ZITHROMAX (azithromycin dihydrate) by Pfizer is drug. Approved for infection. First approved in 1996.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
ZITHROMAX (azithromycin dihydrate) is an oral macrolide antibiotic approved in 1996 for the treatment of bacterial infections. It works by inhibiting bacterial protein synthesis, making it effective against a broad spectrum of gram-positive and gram-negative organisms. Patients take this drug as a tablet for community-acquired infections and other bacterial indications.
The product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating brand teams are likely in transition or cost-management mode with stable but not expanding headcount.
drug. [see ]
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
Zithromax EV in Community-Acquired Pneumonia (CAP)
A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications
Worked on ZITHROMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZITHROMAX offers limited growth opportunity given its LOE-approaching status and mature market position. Career development will likely focus on defensive strategies, cost management, and portfolio optimization rather than brand building or clinical advancement.